Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trialJakob M. Riedl, Armin Gerger, Herbert Stöger et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivityJohannes Lorenz Berg, Armin Zebisch, Bianca Perfler et al.|Leukemia|2021Cited by 8
<i>RAS</i> -mutant clones drive extramedullary acute myeloid leukemiaPanagiota Chaida, Armin Zebisch, Julia Frimmel et al.|bioRxiv (Cold Spring Harbor Laboratory)|2026Cited by 1
1938P Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trialArmin Gerger, Ellen Heitzer, Jakob M. Riedl et al.|Annals of Oncology|2020Cited by 0
EZH2 inactivation drives MAPK-dependent vulnerability to MEK inhibition in RAS-mutant CMMLEva Gruden, Armin Zebisch, Bianca Perfler et al.|bioRxiv (Cold Spring Harbor Laboratory)|2026Cited by 0